BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36270831)

  • 1. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma.
    Hinchcliff E; Rumpf J; Ratan R; Fleming ND; Jazaeri A; Fellman B; Meyer L; Soliman P
    Gynecol Oncol; 2022 Dec; 167(3):490-495. PubMed ID: 36270831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncological outcomes of unexpected uterine leiomyosarcoma: A single-center retrospective analysis of 5528 consecutive hysterectomies.
    Casarin J; Ghezzi F; Lembo A; Artuso V; Schivardi G; Galati EF; Ambrosoli AL; Bogani G; Multinu F; Cromi A
    J Surg Oncol; 2024 Mar; 129(3):517-522. PubMed ID: 37974522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single institute.
    Kodama K; Sonoda K; Kijima M; Yamaguchi S; Yagi H; Yasunaga M; Ohgami T; Onoyama I; Kaneki E; Okugawa K; Yahata H; Ohishi Y; Oda Y; Kato K
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e63-e67. PubMed ID: 31721462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
    Davidson B; Kjæreng ML; Førsund M; Danielsen HE; Kristensen GB; Abeler VM
    Am J Clin Pathol; 2016 Apr; 145(4):449-58. PubMed ID: 27149024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.
    Wang F; Dai X; Chen H; Hu X; Wang Y
    BMC Cancer; 2022 Oct; 22(1):1050. PubMed ID: 36207687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reoperation with Total Hysterectomy after Incomplete Surgery Is Helpful in Patients with Incidentally Diagnosed Uterine Leiomyosarcoma.
    Zhang W; Han Z; Li Z; Zheng Z; Wu X
    Gynecol Obstet Invest; 2021; 86(4):408-414. PubMed ID: 34284401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
    Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
    Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
    Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
    Leitao MM; Hensley ML; Barakat RR; Aghajanian C; Gardner GJ; Jewell EL; O'Cearbhaill R; Soslow RA
    Gynecol Oncol; 2012 Mar; 124(3):558-62. PubMed ID: 22085894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
    Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
    Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study.
    Bizzarri N; Ghirardi V; Di Fiore GLM; De Iaco P; Gadducci A; Casarin J; Perrone AM; Pasciuto T; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2019 Sep; 29(7):1134-1140. PubMed ID: 31420411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes.
    Nathenson MJ; Conley AP; Lin H; Fleming N; Lazar A; Wang WL; Ravi V
    Int J Gynecol Cancer; 2018 Sep; 28(7):1297-1310. PubMed ID: 30044322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
    George S; Barysauskas C; Serrano C; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Demetri GD; Muto MG
    Cancer; 2014 Oct; 120(20):3154-8. PubMed ID: 24923260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.
    Lusby K; Savannah KB; Demicco EG; Zhang Y; Ghadimi MP; Young ED; Colombo C; Lam R; Dogan TE; Hornick JL; Lazar AJ; Hunt KK; Anderson ML; Creighton CJ; Lev D; Pollock RE
    Ann Surg Oncol; 2013 Jul; 20(7):2364-72. PubMed ID: 23334251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
    Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
    Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.
    Kapp DS; Shin JY; Chan JK
    Cancer; 2008 Feb; 112(4):820-30. PubMed ID: 18189292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of stage I occult uterine leiomyosarcoma: effects of morcellation, second-look surgery, and adjuvant treatments on survival.
    Yang J; Yang J; Cao D; Pan L; Wu M; Xiang Y
    Ann Transl Med; 2022 Jan; 10(2):127. PubMed ID: 35282058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.